Survey Finds Wide Gaps in Kidney Cancer Drug Access
Clinicians across 58 countries report uneven availability and reimbursement of advanced renal cell carcinoma therapies.
Updated on Nov. 12, 2026 in Cancer
Live Poll
Do you think a person's country should determine whether they can access new cancer drugs?
A cross-sectional international survey of 144 clinicians in 58 countries assessed the availability and reimbursement of 20 innovative systemic therapies for renal cell carcinoma. The online survey ran from January 31, 2025, to May 1, 2025, and found significant global disparities.
Why it matters
The findings indicate that national income level is significantly associated with access to advanced kidney cancer treatments, suggesting that where a patient lives may shape the therapies they can receive. The results highlight the need for policy attention to reimbursement gaps that affect patient access worldwide.
The survey drew 144 clinicians from 58 countries, 83% of whom were medical oncologists, and assessed 20 systemic therapies for renal cell carcinoma. Six countries (10%) guaranteed full reimbursement for at least 15 therapies, while 18 countries (31%) fully reimbursed none, and the study's underlying cause for these gaps was not addressed in the available data.
The players
ARON Research Foundation
The ARON Research Foundation is a research organization whose network was used to invite clinicians to take part in the survey.
The Oncologist
The Oncologist is a peer-reviewed medical journal focused on oncology research and clinical practice.
The details
Participants were invited through the ARON Research Foundation network and completed a 40-question closed-ended questionnaire covering three categories. The respondents were predominantly medical oncologists (120 of 144), with 19 urologists and 4 radiation oncologists also taking part. The study results were published in The Oncologist.
Timeline
January 31, 2025: Online survey period opened.
May 1, 2025: Online survey period closed.
November 12, 2026: Study results published in The Oncologist.
Health Landscape
The study places renal cell carcinoma treatment access within a wider pattern in which national income shapes access to newer oncology drugs. It measures disparities across 58 countries with differing healthcare and economic systems, offering a population-level view rather than an individual patient perspective.
Patients with advanced kidney cancer may find that the treatments available to them depend heavily on the country where they receive care. Those seeking newer systemic therapies may need to ask their care team about local availability and reimbursement status.
The takeaway
Access to advanced kidney cancer treatment varies widely across the world, so patients and advocates may benefit from checking current drug availability and reimbursement rules in their own country. Understanding these local differences can help people plan conversations with their oncology team.
Further reading
For more on treatment research and access, explore our Cancer coverage.
Source note: This article includes information reported by Renal and Urology News.
Live Poll
Do you think a person's country should determine whether they can access new cancer drugs?
